1. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
   YU SAWADA et al, 2015 CrossRef
2. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
   YOSHITAKA TADA et al, 2013 CrossRef
3. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
   Qunfeng Wu et al, 2017, Molecular Therapy CrossRef
4. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
   Norihiro Fujinami et al, 2016, Biochemistry and Biophysics Reports CrossRef
5. Fragments generated upon extracellular matrix remodeling: Biological regulators and potential drugs
   Sylvie Ricard-Blum et al, 2017, Matrix Biology CrossRef
6. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
   Fubo Zhou et al, 2018, Med Res Rev CrossRef
7. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects
   Yukai He et al, 2014, Immunotherapy CrossRef
8. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma
   Li Wang et al, 2015, Hepatobiliary & Pancreatic Diseases International CrossRef
9. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice
   Tatsuaki Iwama et al, 2016, Biochemical and Biophysical Research Communications CrossRef
10. Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3
    P. Hu et al, 2016, Int J Immunogenet CrossRef
11. Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression.
    Sylvie Brassart-Pasco et al, 2020, Front Oncol CrossRef
12. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
    Quan Liu et al, 2017, Oncotarget CrossRef
13. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
    Yu Akazawa et al, 2020, Cancer Sci CrossRef
14. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses
    Bingfeng Zuo et al, 2022, J Hematol Oncol CrossRef